Dr Jayant Karajgi has been elevated to Chief Executive Officer (CEO) at FTF Pharma, a wholly owned subsidiary of Shilpa Medicare, where he will lead the company’s strategic growth, operational expansion and innovation initiatives.
He announced the development through an update on his LinkedIn profile.
Dr Karajgi brings more than 33 years of experience in the pharmaceutical industry across research, manufacturing, regulatory affairs, laboratory operations, quality and business strategy. Prior to taking over as CEO of FTF Pharma in May 2026, he served as Chief Operating Officer (COO) at Shilpa Medicare from October 2019 to May 2026, where he led the formulations business and oversaw operations across quality, regulatory, sustainability and operational excellence.
Before joining Shilpa Medicare, he worked at Rubicon Research as Chief Operating Officer (COO) from September 2017 to October 2019. Earlier, he served as Chief Scientific Officer at Wockhardt from June 2016 to August 2017 and as President at Aurobindo Pharma from July 2011 to June 2016.
Over the course of his career, he has also been associated with companies including Famycare and Mylan, contributing to product development, innovation, manufacturing operations and business expansion initiatives across the pharmaceutical sector.
